Hang Liao

Dr. Hang Liao

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2025 in Molecules
Verified
Journal Article
Open access
PDF file
MFMarco Francescato
Marco Francescato
HLHang Liao
Hang Liao
Luca GentilucciLuca Gentilucci
Luca Gentilucci
Short- and medium-sized peptides have long been used as effective and versatile organocatalysts. In the early 80s, Inoue used diketopiperazines in the Strecker reaction, while Juliá and Colonna reported the epoxidation of chalcone catalyzed by poly-L-Ala. Since then, a variety of peptide-catalyzed reactions have been described. However, peptide synthesis typically implicates the use of toxic reagents and generates wastes; therefore, peptide recycling is expected to significantly improve the overall sustainability of the process. Easy recovery and recycling of peptide catalysts can be expediently attained by covalent binding, inclusion, or adsorption. In addition, immobilization can significantly accelerate the screening of new peptide catalysts. For these reasons, diverse supports have been tested, including natural or synthetic polymers, porous polymeric networks, inorganic porous materials, organic-inorganic hybrid materials, and finally metal–organic frame-works.

5 March 2026 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
ASAlessandra Stefan
Alessandra Stefan
LGLuca Gentilucci
Luca Gentilucci
HLHang Liao
Hang Liao
AHAlejandro Hochkoeppler
Alejandro Hochkoeppler
Prokaryotic and eukaryotic L-lactate dehydrogenases catalyze both the reduction of pyruvate to L-lactate and the reverse reaction generating the α-ketoacid. Remarkably, the energetic metabolism of human malignant cells is sustained by lactate dehydrogenase A (hLDH-A), the catalytic action of which is committed to its homotetrameric form (denoted hLDH-5), and is coupled to glycolysis. Therefore, hLDH-A represents a substantial druggable target, demanding the search for effective inhibitors of this enzyme. Here we report on the inhibition of hLDH-A exerted by dicarboxylates, whose performance is strictly dependent on their carbon chain length. In particular, the best performers were tetradecanedioic acid, hexadecanedioic acid, and crocetin (a polyunsaturated dicarboxylate), whose addition to assay mixtures strongly inhibited the activity of hLDH-A. Moreover, the inhibition of hLDH-A by hexadecanedioic acid was more effective against the monomeric enzyme than towards its tetrameric counterpart, suggesting that this dicarboxylate interferes with the assembly of hLDH-5. Furthermore, docking simulations support that long-, but not short-chain dicarboxylates, effectively bind to a specific site of monomeric hLDH-A, plausibly preventing its assembly into catalytically-competent hLDH-5. Overall, our observations indicate long-chain dicarboxylates as efficient inhibitors of hLDH-A, prompting to test their action in cellulo.

5 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MFMarco Francescato
Marco Francescato
HLHang Liao
Hang Liao
LCLorenzo Cavina
Lorenzo Cavina
ABAndrea Bedini
Andrea Bedini
Luca GentilucciLuca Gentilucci
Luca Gentilucci
Background: There is currently increasing interest in atypical opioid compounds capable of expanding their clinical applications beyond pain management, including the treatment of psychiatric disorders and substance abuse. In this context, the cyclotetrapeptide c[Trp-Phe-D-Pro-Phe] (CJ-15,208, 1) and its derivatives represent an unusual class of opioid peptides. This compound was found to be a mixed KOR/MOR antagonist in vitro, but it acted as an agonist in vivo. For its diverse analogues, it appeared that receptors’ affinity, selectivity, and agonist/antagonist activity greatly varied upon modifications to backbone geometry and the 3D display of pharmacophores. Methods: We utilized NMR, molecular dynamics, and molecular docking to analyze 3D structures and pharmacodynamic properties of selected representative cyclopeptide analogues of 1. Results: The simulations support that, despite its contradictory functional activity in vitro and in vivo, 1 can bind to the active conformation of receptors in an agonist-like fashion. In general, Trp appeared to be the fundamental pharmacophore in the ligand–receptor complexes. In particular, agonists showed a direct interaction between the indole ring and the carboxylate of the conserved Asp(3:32). Conclusions: These studies support a distinctive pharmacodynamic model for this class of compounds, potentially useful for the design of opioid compounds with novel binding/activity profiles and improved therapeutic effects.